Characteristic No. (%) | 0 h-CA N = 71 (42%) | 1 h-CA N = 71 (42%) | ≥ 2 h-CA N = 26 (16%) | Total N = 168 |
---|---|---|---|---|
Age, years | ||||
Median (range) | 55 (26–67) | 55 (26–67) | 55 (36–65) | 55 (26–67) |
Age > 60, No. (%) | 15 (21%) | 23 (32%) | 9 (35%) | 47 (28%) |
Sex, No. (%) | ||||
Male | 35 (49%) | 36 (51%) | 12 (46%) | 83(49%) |
Female | 36 (51%) | 35 (49%) | 14 (54%) | 85 (51%) |
ISS stage, No. (%) | ||||
Stage1 | 36 (51%) | 24 (34%) | 6 (23%) | 66(39%) |
Stage2 | 20 (28%) | 25 (35%) | 14 (54%) | 59 (35%) |
Stage 3 | 15 (21%) | 22 (31%) | 6 (23%) | 43 (26%) |
R-ISS stage, No. (%) | ||||
Stage1 | 26 (37%) | 10 (14%) | 2 (8%) | 38(23%) |
Stage2 | 40 (56%) | 51 (72%) | 18 (69%) | 109 (65%) |
Stage 3 | 5 (7%) | 10 (14%) | 6 (23%) | 21 (13%) |
Induction regimen, No. (%) | ||||
PI-based | 55 (77%) | 65 (92%) | 14 (54%) | 134 (80%) |
PI and IMiD combination | 12 (17%) | 3 (4%) | 9 (35%) | 24 (14%) |
PI, IMiD and CD38 Ab combination | 4 (6%) | 3 (4%) | 3 (11%) | 10 (6%) |
Response before ASCT, No. (%) | ||||
≥VGPR | 49 (69%) | 54 (76%) | 22 (85%) | 125 (74%) |
<VGPR | 22 (31%) | 17 (24%) | 4 (15%) | 43 (26%) |
Response after ASCT, No. (%) | ||||
MRD negative | 39 (55%) | 37 (52%) | 14 (54%) | 90 (54%) |
MRD positive | 32 (45%) | 34 (48%) | 12 (46%) | 78 (46%) |
Maintenance regimen, No. (%) | ||||
Bortezomib | 54 (76%) | 57 (80%) | 14 (54%) | 125 (74%) |
Lenalidomide | 9 (13%) | 8 (11%) | 3 (12%) | 20 (12%) |
Bortezomib + Lenalidomide | 6 (9%) | 5 (7%) | 8 (31%) | 19 (11%) |
High risk cytogenetics, No. (%) | ||||
Gain or amplification of 1q21 | NA | 57 (80%) | 24 (92%) | 81 (48%) |
del(17p) | NA | 9 (13%) | 8 (31%) | 17 (10%) |
t(4;14) | NA | 5 (7%) | 20 (77%) | 25 (15%) |
t(14;16) | NA | 0 (0%) | 1 (4%) | 1 (1%) |
Other clinical characteristics, No. (%) | ||||
Elevated LDH | 17 (24%) | 18 (25%) | 13 (50%) | 48 (29%) |
Renal dysfunction (Ccr < 60 ml/min) | 12 (17%) | 11 (16%) | 4 (15%) | 27 (16%) |
Hypercalcemia | 7 (10%) | 5 (7%) | 2 (8%) | 14 (8%) |
Anemia | 20 (28%) | 31 (44%) | 10 (39%) | 61(36%) |
Osteolytic lesions | 59 (83%) | 59 (83%) | 22 (85%) | 140 (83%) |
Extramedullary disease (bone-related) | 17 (24%) | 11 (16%) | 3 (12%) | 31 (19%) |
Extramedullary disease (extraosseous) | 5 (7%) | 0 (0%) | 2 (8%) | 7 (4%) |